MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers

Omar Alhalabi, Jianfeng Chen, Yuxue Zhang, Yang Lu, Qi Wang, Sumankalai Ramachandran, Rebecca Slack Tidwell, Guangchun Han, Xinmiao Yan, Jieru Meng, Ruiping Wang, Anh G. Hoang, Wei-Lien Wang, Jian Song, Lidia Lopez, Alex Andreev-Drakhlin, Arlene Siefker-Radtke, Xinqiao Zhang, William F. Benedict, Amishi Y. Shah, Jennifer Wang, Pavlos Msaouel, Miao Zhang, Charles C. Guo, Bogdan Czerniak, Carmen Behrens, Luisa Soto, Vassiliki Papadimitrakopoulou, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Jack Lee, Jack Roth, Stephen Swisher, Ignacio Wistuba, John Heymach, Jing Wang, Matthew T. Campbell, Eleni Efstathiou, Mark Titus, Christopher J. Logothetis, Thai H. Ho, Jianjun Zhang, Linghua Wang, & Jianjun Gao.

Methylthioadenosine phosphorylase, an essential enzyme for the adenine salvage pathway, is often deficient (MTAP<sup>def</sup>) in tumors with 9p21 loss and hypothetically renders tumors susceptible to synthetic lethality by antifolates targeting de novo purine synthesis. Here we report our single arm phase II trial (NCT02693717) that assesses pemetrexed in MTAP<sup>def</sup> urothelial carcinoma (UC) with the primary endpoint of overall response rate (ORR). Three of 7 enrolled MTAP<sup>def</sup> patients show response to pemetrexed (ORR 43%). Furthermore, a historic cohort shows 4 of 4 MTAP<sup>def</sup> patients respond to pemetrexed as compared to 1 of 10 MTAP-proficient patients. In vitro and in vivo preclinical data using UC cell lines demonstrate increased sensitivity to pemetrexed by inducing DNA damage, and distorting nucleotide pools. In addition, MTAP-knockdown increases sensitivity to pemetrexed. Furthermore, in a lung adenocarcinoma retrospective cohort (N = 72) from the published BATTLE2 clinical trial (NCT01248247), MTAP<sup>def</sup> associates with an improved response rate to pemetrexed. Our data demonstrate a synthetic lethal interaction between MTAP<sup>def</sup> and de novo purine inhibition, which represents a promising therapeutic strategy for larger prospective trials.
Despite major advances in immune checkpoint therapy (ICT) and targeted therapy⁴⁻⁹, urothelial carcinoma (UC) remains a major cause of cancer-related deaths across the world and there continues to be an urgent need to better characterize and target distinct molecular subtypes of this disease.¹⁰⁻¹². Loss of the focal chromosomal region 9p21.3 is a common event in UC¹³ that leads to loss of tumor suppressor genes CDKN2A/B and metabolic gene MTAP (Methylthioadenosine phosphorylase)¹⁴,¹⁵ and correlates with adverse clinical outcomes¹⁶⁻²². The MTAP protein is an essential enzyme that controls the salvage synthesis of adenine from the substrate methylthioadenosine (MTA) (Fig. 1a)¹⁴,¹⁵,¹⁹,²³ and correlates with adverse clinical outcomes¹⁶. CDKN2A/B is involved in folate metabolism, namely dihydrofolate reductase, thymidylate synthase, and glycaminide ribonucleotide formyl transferase²⁸. As such, tumor MTAP deficiency may provide a metabolic vulnerability for the use of antifolate agents such as pemetrexed to effectively treat UC with 9p21 loss.

In this work, we test our hypothesis and analyze tumor tissues for MTAP expression status in correlation with clinical responses to pemetrexed in patients with metastatic UC who either enrolled on our phase II clinical trial (NCT02693717) or were historically treated with pemetrexed. We further corroborate our findings mechanistically using preclinical models and clinically using an independent clinical cohort of patients with metastatic lung adenocarcinoma.

**Results**

MTAP loss is prevalent in UC. Based upon genomic data¹³, more than 99% of MTAPdef UC also contains CDKN2A loss. Since we already established a CLIA certified immunohistochemistry (IHC) test to determine MTAP gene expression status, we decided to use MTAPdef as a surrogate biomarker for 9p21 loss. To evaluate the prevalence of MTAP loss in UC, we assessed The Cancer Genome Atlas (TCGA) database for MTAP somatic copy number alterations (SCNAs) and found that 106 of 408 (26%) muscle-invasive UC cases harbored a homozygous deletion of the MTAP gene²⁰ (Fig. 1b). Consistent with TCGA data, IHC analysis of a tumor tissue microarray from 151 UC patients demonstrated that MTAP loss occurred in 27.8% of tumor specimens (Fig. 1c). Of note, we observed no significant difference in the rate of MTAP loss between early-stage and advanced-stage tumors suggesting an early onset of this genomic event (Fig. 1d and Supplementary Table 1).

**Patient characteristics.** In a cohort of 21 patients, including a historical cohort of 14 metastatic UC patients (4 with MTAPdef and 10 with MTAPprof, respectively) treated with pemetrexed beyond first line of therapy (Supplementary Fig. 1) and our current trial cohort of 7 patients (all with MTAPdef) enrolled in clinical trial NCT02693717, the median age was 70 (Table 1). Approximately two thirds of the patients were male. More than half (52%) of the patients had a limited Eastern Cooperative Oncology Group (ECOG) performance status (1 or 2). Prior cisplatin-based chemotherapy was given in 16 of 21 (76%) of patients and prior ICT was given in 6 of 21 (28%) of patients. Patients enrolled in NCT02693717 (09/2017–2/2019) were more likely to have received prior ICT (71%) as compared to patients included in our historical cohort (7%) as patients in the historical cohort were treated before the approval of ICT for UC (9/2014–2/2016). Furthermore, 47% of patients in our entire cohort had received ≥2 lines of prior therapy, as detailed in Table 1.

Pemetrexed is clinically effective against MTAPdef UC. In our historical cohort analysis, all MTAPdef UC patients (4 of 4) had an objective response to pemetrexed (ORR 100%), while only one of the 10 MTAP-proficient (MTAPprof) UC had an objective response (ORR 10%). Notably, 8/10 patients with MTAPprof UC had an increase in tumor volume from baseline as best response (Fig. 1e).

Our prospective study NCT02693717 (Fig. 1f) enrolled 7 patients with previously treated MTAPdef UC but was intentionally terminated early in favor of another trial with pemetrexed plus anti-PD-L1 combination therapy in the same population of patients. The primary endpoint was overall response rate (ORR) to pemetrexed, which was 42% (3 of 7 patients) (Fig. 1g). The secondary endpoints were survival and safety of pemetrexed. After a median follow up of 7.1 months, the estimated median progression-free survival (PFS) is 5.3 months and median overall survival (OS) is 7.7 months. All and treatment-related adverse events (AEs) experienced by patients treated with pemetrexed in our phase II trial are summarized in Supplementary Tables 2 and 3. There were no grade 4 or 5 treatment-related AEs. Most common treatment-related AE was anemia and includes grade 3 anemia in 3 of 7 (43%) of patients. Figure 1h shows an imaging example of a patient with metastatic MTAPdef UC who had a near-complete response to pemetrexed (after progressing through first-line gemcitabine and cisplatin) as compared to a patient with metastatic MTAPprof UC who progressed on pemetrexed (after progressing through first-line gemcitabine and cisplatin).

Antifolates are effective in human MTAPdef UC cell lines and xenograft models by distorting nucleotide pools and inducing DNA double-strand breaks. To further test our hypothesis that MTAP deficiency may create a vulnerability to antifolate agents, we assessed the sensitivity of UC cell lines to pemetrexed. For this purpose, we screened the available human UC cell lines, confirmed MTAP expression status using Western blot, and identified four MTAPprof UC cell lines (HT-1376, T24, HT-1197, and J82) and four MTAPdef UC cell lines (RT112, RT4, UM-UC-3, and 253 J) (Fig. 2a). The T24 cell line was identified as MTAPprof but p16 (product of CDKN2A) deficient (Supplementary Fig. 2a). We also confirmed the functional consequences of MTAP loss by detecting a >30-fold increase in the concentrations of its substrate, MTA, in the culture medium of MTAPdef UC cell lines as compared to the culture medium of MTAPprof UC cell lines (Fig. 2a and Supplementary Fig. 2b), consistent with previous reports.¹⁴,¹⁵,³⁰ We found that the viability of MTAPdef UC cell lines in response to pemetrexed treatment was much lower (IC₅₀ < 0.25 μM) as compared to MTAPprof UC cell lines (IC₅₀ > 20 μM) (Fig. 2b). In addition, we ruled out that accumulating MTA has any impact on the MTAPdef and MTAPprof cell lines viability in the absence or presence of pemetrexed (Supplementary Fig. 3a, b). On the other hand, we did not observe a difference in the viability of MTAPdef cell lines in comparison to MTAPprof cell lines when treated with the antimitabolite gemcitabine, which is commonly used in urothelial cancer (Supplementary Fig. 4a). Notably, the T24 cell line did not demonstrate high levels of sensitivity to pemetrexed (Fig. 2b) despite being p16 deficient, suggesting that loss of p16 alone is not associated with increased sensitivity to pemetrexed and that the increased sensitivity is more likely attributed to MTAP loss. Consistent with
Fig. 1 MTAP deficient metastatic urothelial carcinoma response to pemetrexed. a Schematic illustration of salvage and de novo adenine synthesis pathways in the context of MTAP loss and de novo purine synthesis inhibition. Inhibition of the de novo pathway leads to decreased nucleotide synthesis and eventually tumor cell apoptosis. MTA methylthioadenosine, PRPP phosphoribosylpyrophosphate. b Frequency of MTAP deletion in 408 UC patients in The Cancer Genome Atlas (TCGA) database. HD, homozygous deletion; LOH, loss of heterozygosity; LLG, low-level copy number gain; Ampl, amplification. c, d Frequency of MTAP loss in a tumor tissue microarray. Positive and negative staining of MTAP within 109 MTAPprof and 42 MTAPdef samples are available in Source Data file. Tis, carcinoma in situ; T1, invasive to lamina propria; T2-4a, muscle-invasive carcinoma; N+, metastatic to nodes; M+, systemic metastases. e Waterfall plots for best response of target lesions based on retrospective analysis of patients with metastatic UC treated with pemetrexed. f Clinical trial schema of NCT02693717. g Waterfall plots for best response of target lesions of patients with metastatic UC treated with pemetrexed under NCT02693717. *not evaluable for response; °progressive disease for new lesions. h Example of a patient with metastatic MTAPdef UC who progressed after receiving gemcitabine/cisplatin but responded to pemetrexed, compared to patient with MTAPprof UC who progressed after receiving gemcitabine/cisplatin but didn’t respond to pemetrexed.
MTAPdef UC cells were treated with pemetrexed at a 40-fold lower concentration (0.5 μM) as compared to MTAPprof UC cells (20 μM) (Fig. 2c), suggesting a wide therapeutic window of pemetrexed for MTAPdef UC.

Next, we assessed whether pemetrexed treatment led to increased DNA double-strand breaks (DSBs) in correlation with MTAPdef UC cells were treated with pemetrexed at a 40-fold lower concentration (0.5 μM) as compared to MTAPprof UC cells. However, the difference was not significant.

Upon treatment with pemetrexed (5 μM), NMPs increased by several folds. The fold rise of NMPs had a higher trend in MTAPdef as compared to MTAPprof cell lines (Supplementary Fig. 4b, c).

Additionally, we analyzed an independent large-scale cancer xenograft models of UC, which demonstrated that the MTAPprof tumors (Supplementary Fig. 7a–d). As expected, in vivo pemetrexed treatment also resulted in significantly higher levels of DNA damage (as shown by 53BP1 staining) in MTAPprof UM-UC-3 tumors as compared to the MTAPprof tumors (Supplementary Fig. 7a–d). As expected, in vivo pemetrexed treatment also resulted in significantly higher levels of DNA damage (as shown by 53BP1 staining) in MTAPprof UM-UC-3 tumors as compared to the MTAPprof tumors (Supplementary Fig. 7a–d).

Pemetrexed is effective against MTAP knockdown UC cells. To verify that pemetrexed sensitivity is attributed to loss of MTAP instead of other co-deleted genes in the 9p21.3 region23,25, we selectively knocked down the MTAP gene (MTAPKD) in HT-1376 (a cell line with intact P16 expression), which led to substantial loss of MTAP protein expression and significantly higher levels of DNA damage (as shown by 53BP1 staining) in MTAPprof tumors as compared to the MTAPprof tumors.

L-alanosine, inhibitor of de novo adenine synthesis, is effective against human MTAPdef UC cell lines. To further verify that the
Fig. 2 In vitro and in vivo effects of pemetrexed on human UC based on MTAP protein status. 

**a** Western blot verification of MTAP protein loss in four MTAPdef vs four MTAPprof human UC cell lines paired with UHPLC-ESI/triple quadrupole mass spectrometry measuring MTA concentration in cell media of human UC cell lines (ng/mL). MTA levels are significantly higher in MTAPdef compared to MTAPprof cell lines. *P* value was calculated by Welch T test. 

**b** Sub-G1 analysis of MTAPdef and MTAPprof cell lines when treated with 0.5 μM and 20 μM of pemetrexed (PEM). *P* value was calculated by Mann-Whitney test. 

**c** Cell viability after treatment with increasing concentrations of pemetrexed is significantly higher in MTAPprof compared to MTAPdef cell lines. *P* value was calculated by two-way ANOVA. 

**d, e** Xenograft tumor volume in HT-1376 and UM-UC-3 when treated with pemetrexed vs solvent. *P* value was calculated by two-way ANOVA. 

**f** Western blot and UHPLC-ESI/triple quadrupole mass spectrometry confirmation of MTAP knockdown in two HT-1376 cell lines: shMTAP2 and shMTAP3. 

**g** Pemetrexed resulted in significantly lower viability in the transfected HT1376 compared to the parental cell lines, with or without transduction of the lentivirus control vector. *P* value was calculated by two-way ANOVA. Data in **a** (bottom panel), **b-e**, **f** (bottom panel), and **g** are presented as mean ±/− SD.
synthetic lethal interaction between inhibition of de novo adenine synthesis and tumor MTAP deficiency is a pathway-specific interaction, we tested the sensitivity of MTAP\textsuperscript{def} and MTAP\textsuperscript{prof} cell lines to L-alanosine, a well-known amino acid analog and a potent inhibitor of de novo adenosine monophosphate (AMP) synthesis. Our data indicate that MTAP\textsuperscript{def} cell lines were significantly more susceptible to cytotoxicity from L-alanosine treatment as compared to MTAP\textsuperscript{prof} cell lines (Supplementary Fig. 8a).

Fig. 3 Pemetrexed (PEM) induces significantly higher DNA damage in MTAP\textsuperscript{def} cell lines as compared to MTAP\textsuperscript{prof} cell lines. Eight human bladder cancer cell lines were treated with no treatment (a) or 5 \textmu M of PEM (b) for 24 h. Cells were then fixed and stained with \( \gamma \)-H2AX (red), and 53BP1 (green) antibodies as well as DAPI stain (blue). Images were quantified with ImageJ for \( \gamma \)-H2AX (c) and 53BP1 (d). Data represent mean ± SEM of four fields and analyzed with Welch T test.

Pemetrexed-containing chemotherapy is clinically effective against CDKN2A\textsuperscript{lo}/MTAP\textsuperscript{lo} lung adenocarcinoma. To further validate the correlation between tumor MTAP loss and sensitivity to antifolate agents, we took advantage of the BATTLE-2 trial\textsuperscript{34} that enrolled patients with metastatic nonsmall cell lung cancer, some of which were treated with pemetrexed-containing chemotherapy. Among a total of 200 patients, we identified a cohort of 72 patients with lung adenocarcinoma (LUAD) who were
treated with pemetrexed plus carboplatin and had tumor RNA expression data on both the MTAP and CDKN2A genes (Fig. 4a).

Based on the co-expression of MTAP and CDKN2A, patients were divided into four groups: CDKN2A<sup>hi</sup>/MTAP<sup>hi</sup>, CDKN2A<sup>hi</sup>/MTAP<sup>lo</sup>, CDKN2A<sup>lo</sup>/MTAP<sup>hi</sup>, and CDKN2A<sup>lo</sup>/MTAP<sup>lo</sup> (Fig. 4b).

Given the limitation of having only RNA expression data without copy number data, we chose CDKN2A<sup>lo</sup>/MTAP<sup>lo</sup> as a representative of 9p21 loss and compared it to all other groups.

**Fig. 4 MTAP deficiency leads increased sensitivity to folate-based therapy in lung adenocarcinoma.**

- **a** Retrospective analysis schema for the BATTLE-2 trial.
- **b** Scatterplot of CDKN2A and MTAP RNA expression divided into four distinct groups with CDKN2A<sup>lo</sup>/MTAP<sup>lo</sup> and CDKN2A<sup>hi</sup>/MTAP<sup>hi</sup> having no overlap. MTAP cutoff value was 5.44 and CDKN2A cutoff value was 4.6.
- **c** Response rates to pemetrexed-based therapy in CDKN2A<sup>lo</sup>/MTAP<sup>lo</sup> vs all other groups. Difference is statistically significant by two-sided Fisher’s exact test ($p = 0.0115$).
- **d** Generalized linear regression model evaluating the correlation of 10 most altered genes in lung cancer beside MTAP to estimate the odds ratio and $p$ value for each gene independently. Genes with an odds ratio $>1$ (log (odds ratio) $>0$) and a $p$ value $<0.05$ are considered to be positively correlated with response. Genes with an odds ratio $<1$ (log (odds ratio) $<0$) and a $p$ value $<0.05$ are considered to be negatively correlated with response. Adjustments were made for multiple gene comparisons and $q$ value are presented in supplementary table S5.
- **e** Example of a patient with metastatic CDKN2A<sup>lo</sup>/MTAP<sup>lo</sup> lung adenocarcinoma who partially responded to pemetrexed-based therapy compared to a patient with CDKN2A<sup>hi</sup>/MTAP<sup>hi</sup> lung adenocarcinoma who progressed after pemetrexed-based therapy.
Table 2 Baseline patient characteristics of patients with lung adenocarcinoma at the start of pemetrexed treatment.

| Patient Characteristics | MTAPlo/CDKN2Alow | Others |
|-------------------------|------------------|--------|
| Age (min, max)          | 60.5 (34.0, 82.0) | 59.0 (26.0, 76.0) |
| Gender                  |                  |        |
| Female                  | 16 (67%)         | 23 (51%) |
| Male                    | 8 (33%)          | 22 (49%) |
| Race                    |                  |        |
| Asian                   | 1 (4%)           | 1 (2%)  |
| Black                   | 1 (4%)           | 2 (4%)  |
| White                   | 22 (92%)         | 42 (93%) |
| ECOG PS                 |                  |        |
| 0                       | 1 (4%)           | 2 (4%)  |
| 1                       | 18 (75%)         | 40 (89%) |
| 2                       | 5 (21%)          | 3 (7%)  |
| Kras Mutation           |                  |        |
| No                      | 17 (71%)         | 31 (69%) |
| Yes                     | 7 (29%)          | 14 (31%) |
| EGFR mutation           |                  |        |
| No                      | 14 (58%)         | 37 (84%) |
| Yes                     | 10 (42%)         | 7 (16%) |
| Smoking Status          |                  |        |
| Current                 | 2 (8%)           | 6 (13%) |
| Former                  | 10 (42%)         | 20 (44%) |
| Never                   | 12 (50%)         | 19 (42%) |
| Line of Therapy         |                  |        |
| 1                       | 16 (62%)         | 32 (70%) |
| 2                       | 8 (31%)          | 8 (17%) |
| 3                       | 1 (4%)           | 5 (11%) |
| 4                       | 1 (4%)           | 0 (0%)  |
| 6                       | 0 (0%)           | 1 (2%)  |

MTAPlo MTAP below-median expression, CDKN2Alow CDKN2A below-median expression, ECOG PS Eastern Cooperative Oncology Group performance status.

(variably without 9p21 loss). We noted that objective responses (54%) were significantly higher in CDKN2Alow/MTAPlo patients compared with that (24%) in the rest of patients (p = 0.018 by two-sided Fisher’s exact test) (Fig. 4c and Supplementary Table 4). Of note, among the baseline characteristics of this cohort of patients with LUAD (Table 2), we observed that epidermal growth factor receptor (EGFR) alterations were more prevalent among CDKN2Alow/MTAPlo patients as compared to the rest (42% vs. 16%, P = 0.04). To assess the impact of frequently altered genes in lung cancer, we performed a generalized linear model. However, none of the assessed genes showed a significant positive nor negative association with response to therapy except MTAP (Fig. 4d, Supplementary Table 5). An example of positron emission tomography-computerized tomography of a responding patient with a CDKN2Alow/MTAPlo tumor and a non-responding patient with a CDKN2Alow/MTAPhi tumor is shown in Fig. 4e.

Discussion

Immunotherapy has revolutionized the therapeutic landscape across different cancer types including UC. However, in the foreseen future, chemotherapy agents either alone or in combination with immunotherapy will continue to be one of the main therapeutic modalities for most cancers. In the era of precision medicine, predictive biomarkers, such as genomic alterations for targeted therapy and PD-L1 expression and tumor mutation burden for immunotherapy, are playing an increasingly important role to guide selection of therapeutic strategies. However, there are currently no reliable biomarkers other than tumor histology to guide selection of chemotherapy regimens. In this study, we evaluated the clinical outcomes of patients with UC who were treated with pemetrexed stratified by tumor MTAP protein expression as a surrogate marker for 9p21 status. The sensitivity to antifolates created by MTAP loss was further supported by in vitro and in vivo experiments using human UC cell lines. This sensitivity seemed to be unique to MTAP loss rather than CDKN2A loss, based upon the data that MTAP knockdown in the MTAPprof cell line HT-1376 rendered it sensitive to pemetrexed cytotoxicity whereas loss of the CDKN2A gene product p16 in MTAPPprof cell line T24 did not result in sensitivity to pemetrexed. Mechanistically, antifolates are known to disrupt nucleotide biosynthesis and DNA replication, leading to DNA breakage and programmed cell death. Our findings support this mechanism in MTAPdef and a future direction of ours is to capitalize on this pathway and test combinations that target folates and DNA repair.

Furthermore, in an independent cohort of patients with LUAD, where pemetrexed is commonly used in frontline platinum-based chemotherapy combinations, we found that CDKN2Alow/MTAPlo (surrogate marker for 9p21 loss) patients had significantly higher clinical response rates to such therapy regimens as compared to patients with likely 9p21 intact tumors. Collectively, our data support the hypothesis that tumor MTAP deficiency creates a metabolic vulnerability for therapy with antifolate agents such as pemetrexed. To optimize the clinical utility of our findings, we aim to investigate MTAP among a combination of biomarkers that have been associated with responsiveness to pemetrexed such as TS and DHFR.

We report an observation from clinical data, which we confirmed by performing mechanistic studies and our investigation on MTAP deficiency and antifolate sensitivity is, to our best knowledge, the first in urothelial cancer. One of the few common features among the 21 analyzed patients was their receipt of pemetrexed as second-line therapy or beyond, although their exposure to prior lines of therapy varied. Despite these clinical heterogeneities, our study represents the first effort to assess clinical response to pemetrexed in correlation with a frequent tumor genomic alteration in UC. Our data demonstrate that clinical responses to pemetrexed are enriched in patients with UC containing MTAP loss. These data compare favorably to the previously published data on pemetrexed as a second-line therapy, which showed a modest RR of 28% (13 of 47 patients) in UC without biomarker correlation. In addition, these clinical data in UC are supported by preclinical evidence using human UC cell lines and by an independent cohort of patients with LUAD. Given the association between low MTAP expression and EGFR alterations, it is plausible that antifolates and an EGFR-directed oral tyrosine kinase inhibitor (TKI) could demonstrate synergy. In fact, a recently published phase III randomized trial in patients with advanced LUAD harboring an EGFR-sensitizing mutation showed that adding pemetrexed and carboplatin chemotherapy to gefitinib significantly prolonged PFS and OS. In UC, an association was reported between MTAP loss and FGFR alterations. Therefore, our findings support testing the addition of antifolates to the FDA-approved fibroblast growth factor receptor (FGFR)-directed oral TKI in FGFR-mutant UC.

Pemetrexed has been reported to augment intra-tumor immune responses through increased T cell infiltration/activation along with modulation of innate immune pathways and as a result, enhanced the anti-tumor activity of anti-PD-L1 in pre-clinical models. Based upon the immune-modulatory ability of pemetrexed and its pronounced cytotoxicity in MTAPdef UC, it appears that pemetrexed can be combined with anti-PD-L1 to provide a highly effective treatment for patients with MTAPdef UC. In fact, we have launched a phase II trial assessing a sequential combination of pemetrexed and avelumab (anti-PD-L1 antibody) in patients with MTAPdef UC (NCT03744793). Although this trial led to an intention, early termination of the pemetrexed monotherapy trial in MTAPdef UC, we expect this tissue-rich,
sequential combination trial will shed light on the interaction between pemetrexed and ICT and provide superior therapeutic benefits to patients with MTAP\textsuperscript{def} UC as part of 9p21 loss.

Although the term synthetic lethality classically refers to an interaction between two genetic events, synthetic lethality can also refer to cases in which the combination of a mutation and the action of a chemical compound causes lethality, whereas the mutation or compound alone is non-lethal\textsuperscript{9}. Our data reveal a synthetic lethality strategy to exploit MTAP loss in UC, and potentially in LUAD, by inhibiting de novo adenosine nucleotide synthesis, inducing DNA damage, and potentially distorting nucleotide pools using antifolate agents such as pemetrexed. Loss of MTAP along with adjacent genes such as CDKN2A in the chromosome region 9p21.3 represents one of the most frequent genomic defects existing in 14% of all malignancies and is associated with poor clinical outcomes\textsuperscript{49-50}. Therefore, efforts to develop novel strategies to target MTAP\textsuperscript{def} tumors have increased in recent years, resulting in the identification of a synthetic lethal inhibitor including methionine adenosyltransferase (N-alpha (MTA2), N-methylarginine (MTA1) and N-methyltransferase (PRMT) inhibitors\textsuperscript{14,15,50,51}. This report, we identify an opportunity for a synthetic lethal strategy using a safe agent\textsuperscript{25}, pemetrexed, in MTAP\textsuperscript{def} tumors. These data may be extrapolated to other malignancies that harbor MTAP loss as part of chromosome region 9p21.3 deletion.

Methods

Urothelial carcinoma study population

Trial design, patients, and treatment. NCT02693737 is a single-arm non-randomized phase II trial designed to evaluate pemetrexed disodium in a cohort of patients with metastatic MTAP\textsuperscript{def} UC. MD Anderson Cancer Center (MDACC) and the National Cancer Institute (NCI) sponsored this trial. The trial was approved by the Institutional Review Boards (IRB) of MDACC (MDACC protocol 2015-0592). The primary objective of this trial was to evaluate the overall RR defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The secondary objectives included: 1) evaluating PFS, 2) evaluating OS, 3) evaluating the safety of pemetrexed therapy, 4) collecting blood, urine, and tissue for future translational studies. All primary and secondary outcomes are reported in the manuscript. Enrollment was done between 9/1/2017 and 1/25/2019. Patients provided written consent and the signed consent form was scanned into the electronic medical record. Patients were included from 9/1/2017 and 1/25/2019. Patients provided written consent and the signed consent form was scanned into the electronic medical record. Patients were included from 9/1/2017 and 1/25/2019. Patients provided written consent and the signed consent form was scanned into the electronic medical record. Patients were included from 9/1/2017 and 1/25/2019. Patients provided written consent and the signed consent form was scanned into the electronic medical record. Patients were included from 9/1/2017 and 1/25/2019. Patients provided written consent and the signed consent form was scanned into the electronic medical record. Patients were included from 9/1/2017 and 1/25/2019.

Objective and statistical plan. We analyzed tumor responses to pemetrexed based on MTAP status. Patient characteristics were tabulated. The response was considered to be complete (CR) or partial (PR) per RECIST 1.1. All other responses, including not evaluated were considered non-responders. The proportion of responses for MTAP\textsuperscript{def} vs. MTAP\textsuperscript{prof} were compared with Fisher’s exact test to accommodate the small number of patients. OS was defined as the time from the first day of pemetrexed treatment until death or last contact. PFS was defined as the time from the first day of pemetrexed treatment until disease progression, death, or last disease assessment. Patients alive and without progression at their last assessment were censored on their last date of assessment before starting a new treatment. Kaplan-Meier curves are presented for OS and PFS.

Lung adenocarcinoma study population

Patients and treatment. Among the 10 patients with LUAD enrolled in the BATTLE-2 study\textsuperscript{9,34} and having enough tissue for gene expression analysis, we analyzed the distribution of CDKN2A and MTAP genes to separate patients with 9p21 deletion. Gene expression analysis was done by messenger RNA GeneChip Human Gene 1.0 ST Array from Affymetrix (Santa Clara, CA). CDKN2A and MTAP expression was divided into high (hi) or low (lo) at the median cutoff (Supplementary Figure 5, A, B). Patients then were divided into four groups based on the co-expression of MTAP and CDKN2A: CDKN2A\textsuperscript{hi}/MTAP\textsuperscript{hi}, CDKN2A\textsuperscript{hi}/MTAP\textsuperscript{lo}, CDKN2A\textsuperscript{lo}/MTAP\textsuperscript{lo}, and CDKN2A\textsuperscript{lo}/MTAP\textsuperscript{hi} (Fig. 3b).

Objectives and statistical plan. Next, we evaluated 72 patients with metastatic LUAD treated with pemetrexed-based chemotherapy that has available imaging for disease assessment based on RECIST 1.1. The response was considered to be complete (CR) or partial (PR) per RECIST version 1.1. All other responses, including not evaluated were considered non-responders. The proportion of responses for CDKN2A\textsuperscript{lo}/MTAP\textsuperscript{lo} vs others were compared with Fisher’s exact test to accommodate the small number of patients. OS was defined as the time from the first day of pemetrexed treatment until death or last contact. PFS was defined as the time from the first day of pemetrexed treatment until disease progression, death, or last disease assessment. Patients alive and without progression at their last assessment were censored on their last date of assessment before starting a new treatment. Kaplan-Meier curves are presented for OS, and PFS.

Generalized linear model. To evaluate the association of the 10 altered genes in lung cancer with drug response, generalized linear model (GLM) was used to estimate the odds ratio and p-value for each gene in the lung cancer cohort (n = 72) independently, with 1 indicating a responder and 0 a non-responder. Genes with an odds ratio > 1 (log (odds ratio) > 0) and a p-value < 0.05 are considered to be positively associated with responders. Genes with an odds ratio < 1 (log (odds ratio) < 0) and a p-value < 0.05 are considered to be negatively associated with responders.

Patient samples for tissue microarray IHC.

Patients eligible for enrollment were those seen at Mayo Clinic (Scottsdale, Arizona) who were >18 years old, able to provide informed consent, and undergoing evaluation for genitourinary diseases. Patients were contacted during routine clinical visits or in preparative settings within Mayo Clinic departments and divisions, including urology, radiation oncology, pathology, and medical oncology. Patients were excluded if they declined to participate or if the banking of their biospecimens would compromise the availability of tissue for diagnosis and standard clinical care. The protocol for collecting biospecimens, the process for consenting patients, and the current informed consent form were approved by the Mayo Clinic IRB (protocol no. 08-000980). Patients were enrolled from June 1, 2010, through January 1, 2013. Patients provided written consent and the signed consent form was scanned into the electronic medical record. Patients also received a copy of the signed consent form.

Genomics of drug sensitivity in cancer (GDSC) data.

We analyzed an independent large-scale cancer cell line drug sensitivity dataset, the GDSC\textsuperscript{31}. Analysis was performed using IC\textsubscript{50} values (drug concentration that reduces viability by 50%). MTAP deficiency in cell lines was determined from copy number variation (CNV) in MTAP from the Cancer Cell Line Encyclopedia (CCLE)\textsuperscript{32}. Log2 ratio cutoff values ≤−3 were used to detect deep deletions for each CCLE pan-cancer cell line. Only cell lines with CNV status consistent with low expression of MTAP were included. UM-UC3 was excluded as the IC\textsubscript{50} value in the public database was not reproducible with our repeated experiments using methotrexate. 5637 was excluded as it contained an amplification of the MTAP gene. However, the MTAP protein was only expressed in the nucleus based upon our IHC study. Therefore, the enzymatic activity of MTAP was likely restricted and functionally represented an MTAP\textsuperscript{def} cell line. We tested the difference in IC\textsubscript{50} between UC cell lines with or without deep deletion in MTAP by using a one-sided Wilcoxon rank-sum test.

Mice, cell lines, and reagents.

Athymic nude 6-week-old mice were purchased from the Charles River Laboratory. All in vivo experiments used male mice. All cell lines were originally obtained from ATCC (Manassas, VA), except for RT112 from Creative Bioarray (Shirley, NY). HT-1376, HT-1197, B2, and UM-UC-3 were maintained in MEM supplemented with 10% FBS, 2 mM L-glutamine, and 0.1 mM non-essential amino acids. 253 J was maintained in RPMI1640 plus 10%FBS. T24 and RT4 were maintained in McCoy’s 5A plus 10% FBS. Only mycoplasma-free cultures were used. Pemetrexed (Almitra\textsuperscript{a}) was obtained from Eli Lilly & Co (Indianapolis, IN). L-salolines were purchased from MedKoo Biosciences (Morristown, NJ). Gemcitabine was obtained from SellekChem (Houston, TX). Adenine and 5′-deoxygen-5′-methylthioadenosine (MTA) were obtained from MilliporeSigma (Burlington, MA).

Antibodies and Western blot.

For Western blotting, cells were homogenized in RIPA buffer (Cell Signaling, Danvers, MA) plus phosphatase and protease inhibitor
cocktail, 10 mM NaF, 1 mM PMSE and 1 mM Na3VO4. Protein extracts were purified, and concentrations were measured with Pierce Protein Assay kit (Thermo Fisher Scientific). The following antibodies were used in this study: Anti-MTAP antibody (Rabbit polyclonal, 1:2000) from ProteinTech, anti-poly (ADP-ribose) polymerase-1 (PARP-1) antibody (Rabbit monoclonal, 1:2000) from Cell Signaling (Danvers, MA), and β-actin (Mouse monoclonal, 1:10000) from MilliporeSigma (Burlington, MA). We assessed the cleavage of PARP-1 using Western blot. PARP-1 cleavage at 53 kDa and 20 kDa peaks were observed and the band intensity was measured using ImageJ55.

Immunohistochemistry and immunofluorescent staining. MTAP immunohistochemical staining was performed on a 4 μm unstained slide of a formalin-fixed paraffin-embedded (FFPE) tissue microarray using an automated immunohistochemical staining platform (Leica Bond III, Leica Biosystems, Buffalo Grove IL). Following deparaffinization and rehydration, antigen retrieval was performed at 95 °C for 30 min with citrate buffer, pH 6.0. Endogenous peroxidase was blocked with 3% peroxide for 5 min. Primary anti-methylphosphorylase antibody (ProteinTech, Rosemont, IL) was applied at 1:1200 dilution for 15 min. Primary antibody detection was carried out using a commercial polymer system (Bond Polymer Refine Detection, Leica Biosystems, Buffalo Grove IL), and stain development was achieved by incubation with DAB and DAB Enhancer (Leica Biosystems, Buffalo Grove IL). Tumor cells were assessed for the presence or absence of labeling, defined as the presence of any staining or complete loss of staining, respectively. γ-H2AX and 53BP1 immunofluorescent staining for 8 cell lines was performed with Nunc Lab-Tek II 8-well chamber slides system (ThermoFisher, Waltham, MA). Briefly, cells were plated in individual wells at about 70–80% confluence. Five μm peel off filter without coating was then added into medium, and cells were cultured for additional 24 h. At the end of treatment, anti-γ-H2AX (1:200, MilliporeSigma) or anti-53BP1 (1:200, Cell Signaling) were added to slides after fixation and permeabilization. For 53BP1 staining on FFPE slides, deparaffinization, rehydration, and antigen retrieval were processed the same as immunohistochemistry. Antibody (1:200) was then placed to tissues and incubated for 30 min at room temperature. Positive signals were captured with EVOS M5000 fluorescence microscope (ThermoFisher, Waltham, MA). At least 3 areas at 20x magnification were taken from each slide for further data analysis. Fluorescence processing and quantification were performed with ImageJ55.

Cell viability assay. Cell viability was determined by MTT assay. Briefly, cells were plated at a density of 2,000 cells per well in 96-well cell culture plates. Cells were then treated at densities of 0.5, 1, or 2 μM for 2 h. Insoluble MTT metabolites were dissolved with DMSO at 100 μL/well, and absorbance was measured at 530 nm with background subtraction. IC50 values were then calculated with Graphpad Prism 7.0 software.

MTA and nucleotide pool quantification using ultra-high-performance liquid chromatography-electrospray ionization (UHPLC-ESI)-triple quadrupole mass spectrometry (m/z). MTA was determined in 106 cells 10 cm dishes in triplicate and cultured for 48 h. Culture media and cell pellets were collected separately and kept at −80 °C until measurement. At the day of quantitation, cell pellet was vortexed with 0.6 mL of methanol containing 25 ng of MTA/adenosine internal standard, centrifuged at 12,000 rpm (15300 x g) for 5 min. The supernatant was decanted and evaporated under nitrogen. Each sample was reconstituted in 100 μL water. Cell line media (250 μL) was processed as cell pellets. An Agilent UHPLC Infinity II system was combined with a Chromolith reverse phase column (100 x 2 mm, 1.5 μm, MilliporeSigma, Billerica, MA). Mobile phases used were (A) 0.1% formic acid and water and (B) 0.1% formic acid and methanol at a flow rate of 0.3 mL/min. The mobile phase gradient was held at 20% B for 2 min, and the gradient was ramped up to 95% B in 5 min then held at 95% B for 2 min before being reduced to 80% A and then re-equilibrated for 2 mins. The column temperature was 30 °C and the injection volume was 5.0 μL. Molecules were introduced into a Jet Stream electrospray ionization source to an Agilent 6545 Q-TOF mass spectrometer (Agilent, Santa Clara, CA). The source was operated in a positive ion mode under optimum conditions.

Nucleosides were identified by retention time and parent product ion transitions for MTA quantitative ion (m/z 297.81–36.1) and qualitative ion (m/z 297.81–113.0), and quantified using MassHunter software (Agilent, Santa Clara, CA). A negative ionization method was developed on the Agilent 6495 LC-MS-MS to determine mono and tri-phosphate nucleotide levels. A Phenomenex SEPA column (2.1 x 50 mm, 3.5 μm) was used with a gradient of Buffer A: 5 mM ammonium acetate and Buffer B: Acetonitrile. The cell pellets were harvested and extracted with 100 μL methanol/water (1:1) spincycled with 25 μL of 0.1% TFA, C13-ATP, and C13-dGTP, the vortexed for 1 min and placed on ice for 10 min. After centrifugation at 11,000 rpm (12,800 x g) at 4 °C for 15 min, the supernatant was diluted with 1350 μL 60% Methanol before loading onto an OASIS HLB cartridge (Waters Corp., Milford, MA) that had previously been activated with methanol and water according to the SPE protocol. The final eluent (200 μL) was derivatized with MBSTFA (75 μL) and the derivatization reaction was completed over 5 min with consistent vortex. The samples were then centrifuged at 11,000 rpm for 15 min and 10 μL of the supernatant was injected in triplicate. Under optimal conditions, the lower limit of quantitation (LLOQ) was 0.1 ng/mL.

MTAP knockdown. Lentiviral particles of human short hairpin RNAs (shRNAs) specific to the MTAP gene and control scramble shRNA were purchased from Santa Cruz Biotechnology (Dallas, TX). Transduction of the HT-1376 cell line was carried out according to the manufacturer’s instructions. Briefly, cells were cultured in 12-well plates to reach 50% confluence, transduced with lentiviral particles, split into 100 mm plates, and then selected with 2 μg/mL puromycin-containing culture medium. Single-cell colonies were selected and expanded in puromycin-containing culture medium. RT-PCR and Western blot were then used to confirm the extent of individual MTAP gene knockdown.

Determination of cell cycle distribution by flow cytometry. Cells were plated in 6-well plates and treated with pemetrexed for 72 h. At the end of treatment, cell cycle distribution was determined by propidium iodide (PI) staining (MilliporeSigma, Burlington, MA). Cells were collected and adjusted to a concentration of 106 cells/mL, fixed by 75% ethanol for more than 1 h, and then treated with RNAse A for 30 min at room temperature. After 1 h incubation with PI staining buffer at room temperature, FACScanto II flow cytometry (BD Biosciences, San Jose, CA) was used to detect cell cycle57. When apoptotic cells are stained with PI and analyzed with a flow cytometer, they display a broad G1 (hypodiploid) peak, which can be easily discriminated from the narrow peak of cells with normal (diploid) DNA content in the red fluorescence channels. Each experiment was repeated at least three times.

 Xenograft animal models and in vivo toxicity studies. Animal experiments were carried out under conditions adhering to approved protocols from the Institutional Animal Care and Use Committee at MDACC. Briefly, anesthetized mice were injected in the right flank subcutaneously with 106 UM-UC-3, HT-1376, HT-1376/shCtrl, or HT-1376/shMTAP cells at day 0. Tumor growth was monitored by measuring tumor size with a caliper once a week. After tumor size reached about 50–100 mm3, the dose of pemetrexed for both models was 200 mg/kg with a frequency of three times a week. Tumor volume was calculated using a caliper. Mice were euthanized when tumor size reached 1.5 cm in diameter, ulceration reached 0.2 cm, or moribund occurred, and were recorded as deaths.

Statistical analysis of in vitro and in vivo data. All measurement data were expressed as mean ± standard deviation. If not stated otherwise, comparisons between groups were made using the t test. P values less than 0.05 were considered significant.

Data availability. The data generated or analyzed during this study are included in this published article, its Supplementary Information and Source Data files. For TCGA BLCA cohort shown in Fig. 1b, the genomic data can be retrieved from NCI Genomic Data Commons (NCI-GDC: https://gdc.cancer.gov). Publicly available datasets pertaining to Supplementary Fig. 2a can be downloaded from https://depmap.org/portal/download/. Tissue microarray data pertaining to Fig. 1c, d is included in Source Data file. Clinical data pertaining Fig. 1e, g, h is included in Source Data file. Uncropped Western Blot gels and in vitro data pertaining to Fig. 2a-g is included in Source Data file. Clinical data and gene expression data pertaining to Fig. 4a–e is included in Source Data file. Additional data related to the current study, including the study protocol of the clinical trial NCT02693717, are available from the corresponding author (Janjun Gao) on reasonable request that does not include confidential patient information. Source data are provided with this article.

Received: 18 September 2020; Accepted: 10 March 2022; Published online: 04 April 2022

References
1. Patel, M. R. et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 19, 51–64 (2018).
5. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558 (2014).

4. Sharma, P. et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 17, 1590–1598 (2016).

6. Apolo, A. B. et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 18, 1483–1492 (2017).

7. Bellmunt, J. et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N. Engl. J. Med. 376, 1015–1026 (2017).

8. Taberner, J. et al. Phase I Dose-Escalation Study of INJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. J. Clin. Oncol. 33, 3401–3408 (2015).

9. Ramonalle, M., Loterio, Y., Lebrut, T. & Sorria, J.-C. Novel therapeutic targets in advanced urothelial carcinoma. Crit. Rev. Oncol./Hematol. 98, 106–115 (2016).

10. Choi, W. et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat. Rev. Urol. 11, 400–410 (2014).

11. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J. Clinicians 68, 394–424 (2018).

12. Han, G. et al. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat. Commun. 12, 5606 (2021).

13. Kevalgaonkar, G. V. et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 351, 1214–1218 (2016).

14. Mavrikas, K. J. et al. Disordered methionine metabolism in MTAP-CDKN2A-deleted cancers leads to dependence on PRMT5. Science 351, 1208 (2016).

15. Simonette, M. et al. Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene 19, 6317–6323 (2000).

16. Rebourissou, S. et al. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder cancer. J. Pathol. 227, 315–324 (2012).

17. Chapman, E. J., Harnden, P., Chambers, P., Johnston, C. & Knowles, M. A Comprehensive Analysis of <em>cdkn2a</em> Status in Microdissected Urothelial Cell Carcinoma Reveals Potential Haplosufficiency, a High Frequency of Homozygous Co-deletion and Associations with Clinical Phenotype. Clin. Cancer Res. 11, 5740 (2005).

18. Sasaki, S. et al. Molecular processes of chromosome 9p21 deletions in human cancers. Oncogene 22, 3792–3798 (2003).

19. Stadler, W. M. & Olopade, O. I. Chromosome 9 deletions in bladder cancer cell lines: large homozygous deletions inactivate the CDKN2A, CDKN2B and MTAP genes. Urological Res. 24, 239–244 (1996).

20. Bartolletti, R. et al. Loss of P16 expression and chromosome 9p21 LOH in primary resistance to immune checkpoint therapy. Eur Urol Oncol. 3, e172411 (2017).

21. Fedoriw, A. et al. Anti-tumor Activity of the Type I PRMT Inhibitor, GSK366875, Synergizes with PRMT5 Inhibition through MTAP Loss. Cancer Cell 36, 100–114.e12 (2019).

22. Marjon, K. et al. MTAP Deletions in Cancer Create Vulnerability to Targeting the Metabolite Phosphorylase as Target for Chemoselective Treatment of T-cell Acute Lymphoblastic Leukemia Cells. Cell Death Dis. 7, 422–427 (2016).

23. Schaer, D. A. et al. The folate pathway inhibitor pemetrexed pleiotropically inhibits multiple folate-requiring enzymes. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 24, 3451–3457 (2006).

24. Sweeney, C. J. et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 24, 1567–1573 (2006).

25. Noronha, V. et al. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 38, 124–136 (2020).

26. Bratalsky, G. et al. Novel synthetic lethality (SL) anti-cancer drug target in urothelial bladder cancer (UCB) based on MTAP genomic loss: Incidence and correlations in standard of care (SOC). J. Clin. Oncol. 39, 485–485 (2021).

27. Alhalabi O. et al. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol. S2588-9311(20)30188-7 (2021). https://doi.org/10.1016/j.euo.2021.10.006. Epub ahead of print.

28. Schar, D. A. et al. The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy. Clin. Cancer Res., clincanres 0433, 2019 (2019).

29. Hartwell, I. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating Genetic Approaches into the Discovery of Anticancer Drugs. Science 278, 1064 (1997).

30. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 499, 889–905 (2013).

31. Ducker, G. S. & Rabinowitz, J. D. One-Carbon Metabolism in Health and Disease. Cell Metab. 25, 27–42 (2017).

32. Li, Z. et al. Method for Quantification of Ribonucleotides and Deoxyribonucleotides in Human Cells Using (Trimethylsilyl)diazomethane Derivatization Followed by Liquid Chromatography-Tandem Mass Spectrometry. Anal. Chem. 91, 1019–1026 (2019).

33. Riccardi, C. & Nicoletti, I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat. Protoc. 1, 1488 (2006).
Acknowledgements
We would like to acknowledge Gary Gallick, who sadly passed away, for his significant contributions to this research work. This study was supported in part by the Doris Duke Clinical Scientist Development Award (JF, #2018097) granted to J.G. and L. W. In addition, this study was supported by the MD Anderson Physician Scientist Award, Khalifa Physician Scientist Award, Andrew Sabah Family Foundation Fellows Award, MD Anderson Faculty Scholar Award, David H. Koch Center for Applied Research of Genitourinary Cancers, Wendy and Leslie Irwin Barnhart Fund, Joan and Herb Kellieher Charitable Foundation, and NCI/NIH R01 CA254988-01A1 Award provided to J.G. This study was also supported by SMF Core Grant CA016672 (SMF) and the IRG start-up research funds provided to L.W. by MD Anderson Cancer Center (MDACC). We thank Dr. C. Liu, X. Liu, and P. Xiong from the MD Anderson Sequencing and ncRNA Program, Dr. E. J. Thompson and D. P. Fullof from the SMF Core for their excellent technical assistance. This work was in part supported by the generous philanthropic contributions to The University of Texas MD Anderson Lung Moon Shot Program and the MD Anderson Cancer Center Support Grant P30 CA016672. We would like to acknowledge the GEMINI Team at MD Anderson Cancer Center. P.M. is supported by a Young Investigator Award by the Kidney Cancer Association, a Career Development Award by the American Society of Clinical Oncology, and by the MD Anderson Khalifa Scholar Award. We thank all the patients who participated in this study. O.A. is supported by a Young Investigator Award by American Society of Clinical Oncology. J.A.R. has received grants from Varian Medical Systems. Figure 1f and Supplementary Fig. 1a were created with a licensed version of BioRender.com. The sponsor had no role in the study design, data collection and analysis or manuscript writing.

Author contributions
J.G., L.W., and T.H. conceived and jointly supervised this study. O.A., Y.L., M.T.C., A.Y.S., L.L., and Q.W. collected samples and clinical information. J.C., Y.Z., W.W., J.S., S.R., A.G.H., X.Z., and M.T. carried out experiments. O.A., J.C., X.Y., G.H., C.C.G., P.M., C.J.L., T.H.H., J. Z., L.W., and J.G. analyzed and interpreted data. R.S.T. performed the statistical design and analysis of clinical data. E.E., M.Z., C.C.G., C. B., L.S., and B.C supervised the anatomical pathology staining. O.A., J.C., W.W., J.S., J.L., A.A-D., W.F.B., Jennifer Wang, J.M., A.S-R., V.P., J.Lewis, W.R., V.R., J.Lee, J.R., S.S, I.W., J.H., Jing Wang, and L.W. contributed to the generation of figures and tables. O.A., J.C., L.W., and J.G. wrote and revised the manuscript. All authors approved the manuscript.

Competing interests
Dr. Shah has honorarium with Pfizer, BMS, Exelixis and research funding from BMS, Eisai, and EMD Serono. Dr. Siefker-Radtkeservest as a consultant for Janssen, Merck, the National Comprehensive Cancer Network, Lilly, Bristol-Myers Squibb, AstraZeneca, BioClin Therapeutics, Bavarian Nordic, Seattle Genetics, Nektar, Genentech, Invivo Pharmaceuticals, and EMD Serono. Dr. Siefker-Radke has received research funding from the National Institute of Health, Michael and Sherry Sutton Fund for Urothelial Cancer, Janssen, Takeda, Bristol-Myers Squibb, BioClin Therapeutics, and Nektar. Dr. Campbell has served as a consultant or has provided non-branded educational lectures with honorarium with Pfizer, EMD Serono, AstraZeneca, Eisai, Apricuty, Roche, Bristol Myers Squibb, and Merck. Dr. Gao serves as a consultant for ARMO Biosciences, AstraZeneca, Jouance, Nektar, and Pfizer. Dr. Maouel has received honoraria for service on a Scientific Advisory Board for Mirati Therapeutics, Exelixis, and BMS, consulting for Axiom Healthcare Strategies, non-branded educational programs supported by Exelixis and Pfizer, and research funding for clinical trials from Takeda, BMS, Mirati Therapeutics, Gateway for Cancer Research, and UT MD Anderson Cancer Center. Jack A. Roth has consultancy, stock, Genprex, Inc.; patents issued and pending. Dr. Ho has received honoraria from Exelixis, Genentech, EMD-Serono, Pfizer, Macrogenics, Cardinal Health, Ipsen, and Aveo. The remaining authors declare no conflicts of interest.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-022-29397-z.

Correspondence and requests for materials should be addressed to Linghua Wang or Jianjun Gao.

Peer review information Nature Communications thanks Ao Yuan and the other anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022